PURE Bioscience Raises $1.27 Million from Warrant Exercise

SAN DIEGO–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented silver dihydrogen citrate (SDC)
antimicrobial, announced today that the Company raised $1.27 million
from the recent exercise by all of the holders of the 2,820,670 warrants
expiring May 23, 2016.
Use of proceeds will include the commercialization of FDA approved PURE
Control® antimicrobial as a processing aid for fresh produce and for raw
poultry. PURE Control is a superior, broad spectrum, non-toxic
intervention to prevent foodborne illness and dramatically reduce Salmonella,
Listeria and E. coli during processing.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobialproducts primarily in the food safety
arena — providing solutions to the health and environmental challenges
of pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria to
form a resistance to it. PURE is headquartered in El Cajon, California
(San Diego metropolitan area). Additional information on PURE is
available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from the
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s failure
to implement or otherwise achieve the benefits of its proposed business
initiatives and plans; acceptance of the Company’s current and future
products and services in the marketplace, including the Company’s
ability to convert successful evaluations into customer orders; the
ability of the Company to develop effective new products and receive
required regulatory approvals for such products, including the required
data and regulatory approvals required to use its SDC-based technology
as a direct food contact processing aid in raw poultry and raw meat
processing; competitive factors; dependence upon third-party vendors,
including to manufacture its products; and other risks detailed in the
Company’s periodic report filings with the Securities and Exchange
Commission (the SEC), including its Form 10-K for the fiscal year ended
July 31, 2015, its Form 10-Q for the first quarter ended October 31,
2015 and its Form 10-Q for the second quarter ended January 31, 2016.
You should not place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of this
release.